Thaumaturgical Analysis of CytRx

November 21, 2014 – Although I didn’t give enough weight to the overall drag on shareholder value that the two reversed pentacle court cards implied, this has been an accurate assessment with one exception.  It didn’t give a hint to the FDA partial clinical hold though the effect was not as severe as I would have thought thereby confirming that investor sentiment has made a turn toward the positive here.  I’ll remain patient as I’m underwater by only $0.12 and anticipated a lifting of the partial hold and good OS data later in December.

We’ll see…